Jean Francois Bonfanti

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship
    Jean Francois Bonfanti
    Johnson and Johnson Pharmaceutical Research and Development, Medicinal Chemistry Department, Campus de Maigremont BP315, F 27106 Val de Reuil, France
    J Med Chem 50:4572-84. 2007
  2. ncbi Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121)
    Jean Francois Bonfanti
    Medicinal Chemistry Department, Johnson and Johnson Pharmaceutical Research and Development, Campus de Maigremont, BP 615, F 27106 Val de Reuil, France
    J Med Chem 51:875-96. 2008
  3. ncbi 1,5-benzodiazepines, a novel class of hepatitis C virus polymerase nonnucleoside inhibitors
    Origene Nyanguile
    Tibotec BVBA, Generaal De Wittelaan L11B 3, 2800 Mechelen, Belgium
    Antimicrob Agents Chemother 52:4420-31. 2008
  4. ncbi Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection
    Jean Francois Bonfanti
    Tibotec, a Division of Janssen Cilag, Department of Medicinal Chemistry, Campus de Maigremont BP615, Val de Reuil Cedex, France
    Curr Opin Drug Discov Devel 12:479-87. 2009
  5. ncbi Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein
    Dirk Roymans
    Tibotec BVBA, B 2800 Mechelen, Belgium
    Proc Natl Acad Sci U S A 107:308-13. 2010

Collaborators

Detail Information

Publications5

  1. ncbi Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship
    Jean Francois Bonfanti
    Johnson and Johnson Pharmaceutical Research and Development, Medicinal Chemistry Department, Campus de Maigremont BP315, F 27106 Val de Reuil, France
    J Med Chem 50:4572-84. 2007
    ..We were able to identify new respiratory syncytial virus inhibitors with shorter half-lives in lung tissue...
  2. ncbi Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121)
    Jean Francois Bonfanti
    Medicinal Chemistry Department, Johnson and Johnson Pharmaceutical Research and Development, Campus de Maigremont, BP 615, F 27106 Val de Reuil, France
    J Med Chem 51:875-96. 2008
    ..This paper describes a molecular modeling study followed by a lead optimization program that led to the recovery of the initial potent antiviral activity and the selection of TMC353121 as a clinical candidate...
  3. ncbi 1,5-benzodiazepines, a novel class of hepatitis C virus polymerase nonnucleoside inhibitors
    Origene Nyanguile
    Tibotec BVBA, Generaal De Wittelaan L11B 3, 2800 Mechelen, Belgium
    Antimicrob Agents Chemother 52:4420-31. 2008
    ..The specificity for the HCV target was evaluated by profiling the 1,5-BZDs against other viral and human polymerases, as well as BZD receptors...
  4. ncbi Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection
    Jean Francois Bonfanti
    Tibotec, a Division of Janssen Cilag, Department of Medicinal Chemistry, Campus de Maigremont BP615, Val de Reuil Cedex, France
    Curr Opin Drug Discov Devel 12:479-87. 2009
    ..This review will discuss the status and latest developments of compounds and antibodies that inhibit hRSV fusion...
  5. ncbi Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein
    Dirk Roymans
    Tibotec BVBA, B 2800 Mechelen, Belgium
    Proc Natl Acad Sci U S A 107:308-13. 2010
    ..Rather than completely preventing 6HB formation, our data indicate that TMC353121 inhibits fusion by causing a local disturbance of the natural 6HB conformation...